A new study reveals that precision oral appliance therapy devices, developed by ProSomnus Inc, are effective in treating patients with obstructive sleep apnea (OSA). The study is published in the Cureus Journal of Medical Science.

Key findings from the study include:

  • 89% of all patients and 98.5% of mild to moderate OSA patients were treated to an apnea-hypopnea index (AHI) of fewer than 10 events per hour.
  • 80% of severe OSA patients were treated to an AHI of fewer than 20 events per hour with a 50% improvement.
  • After a minimum one-year follow-up period, 96% of patients continued using their precision OAT devices.

“My experience with ProSomnus began in 2019, and since that time, I have come to appreciate the benefit to my patients in delivering precision oral appliances such as these. The study irrefutably demonstrates this,” says Aditi Desai, BDS, MSc, FCGDent, a co-author of the study, in a release. “The ethos of the company has certainly helped drive the field of oral appliance therapy as a most credible alternative to CPAP.”

ProSomnus also announced additional clinical research highlighting the efficacy, decreased AHI incidents, and strong therapy adherence associated with the company’s precision OAT devices:

  • In a six-center study assessing the efficacy, repeatability, and predictability of treating 58 moderate to severe OSA patients with ProSomnus EVO and a standard treatment protocol, participants’ median obstructive AHI decreased from 20.54 to 3.9 events per hour, while 90% of patients experienced fewer than 15 events per hour. The data were presented at the 2023 Interdisciplinary Belgian Dental and Surgical Sleep Medicine Academy meeting by Marc Braem, DDS, PhD, in an abstract titled “Oral appliance treatment in general hospital setting: effects on obstructive apnea-hypopnea index (oAHI) measured with polygraphy, at multiple general hospitals.”
  • In a study of 22 mild to moderate OSA patients, the ProSomnus EVO was associated with a decreased AHI and strong compliance. After being treated with the EVO, patients’ median AHI decreased from 21 to 4 events per hour, while 95% of patients experienced fewer than 10 events per hour. Patients’ compliance with the EVO, reported in the first three months of therapy, was 100%. These findings were presented at the 2023 World Sleep Congress by Raquel Silva, MD, in an abstract titled “New generation oral appliances for treatment of obstructive sleep apnea.”

“These studies demonstrate that precision oral devices offer consistent efficacy across multiple clinical and hospital settings and are associated with reliable adherence. Traditional oral devices are typically associated with inconsistent efficacy due to imprecise repositioning and stabilization of the jaw and unreliable durability due to side effects and mechanical issues,” says Len Liptak, ProSomnus CEO, in a release. “This new data adds to a body of evidence underscoring that ProSomnus devices are a safe and efficacious option for millions of OSA patients who have terminated or refused CPAP, or been impacted by the CPAP recall.”